A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need.
about
Vanoxerine: cellular mechanism of a new antiarrhythmicThe long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study)A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in womenBirth weight is a significant risk factor for incident atrial fibrillation.Ion channel trafficking: a new therapeutic horizon for atrial fibrillationCardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discoveryInternal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation.Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.The Role of Pericardial and Epicardial Fat in Atrial Fibrillation Pathophysiology and Ablation Outcomes.Pharmacological treatment of persistent atrial fibrillation in the older adult: evidence-based practice.Recent advances in in vivo screening for antiarrhythmic drugs.Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals.The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an I Ks transgenic mouse.Does health-related quality of life predict hospitalization or mortality in patients with atrial fibrillation?
P2860
Q24626475-AA7C8B13-7A8E-45CB-96A9-760EBCC28FEBQ33894513-D5A4BB3F-A398-47B0-AD60-942E9FB5030FQ33992740-F13A64C3-AA0E-4C08-98FB-B296B956FF2EQ34082047-3B941A94-3F64-43C4-848B-4836DBD11D14Q34101658-128F7405-E6B4-4C2A-A16A-8746CB6225FDQ34111355-044E7254-2D06-4C61-8F83-F3C3F0477615Q35180923-43AC93C2-9D23-4A90-AE07-A444E2A6448BQ36518152-114F749B-F857-48CD-9091-5E72DF7A5AF1Q37332761-8A1D12C7-E142-4B65-9BFF-070775B7EF92Q37495963-0AF9B329-3451-4780-847A-E80F00C28DC0Q37847635-DB03852E-629B-4F84-AFED-89F41DD8B922Q38073317-2F886ED7-D474-4EDE-93C1-51A074AD6801Q38253047-6EC06C2F-68D0-49E9-9C2F-D1837D89598DQ38643358-0E03B830-5F9F-4345-83C0-32DE9290A439Q39851183-AB41EA26-FD06-4EBC-995B-070B352D3FCCQ46897772-97EEEB95-9D0D-4CA1-A34C-6A770377CC54Q48156231-2B61B393-908B-41E9-B52D-549DF65FED67
P2860
A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A perspective on antiarrhythmi ...... : there remains an unmet need.
@ast
A perspective on antiarrhythmi ...... : there remains an unmet need.
@en
type
label
A perspective on antiarrhythmi ...... : there remains an unmet need.
@ast
A perspective on antiarrhythmi ...... : there remains an unmet need.
@en
prefLabel
A perspective on antiarrhythmi ...... : there remains an unmet need.
@ast
A perspective on antiarrhythmi ...... : there remains an unmet need.
@en
P1476
A perspective on antiarrhythmi ...... : there remains an unmet need.
@en
P2093
Albert L Waldo
P304
P356
10.1016/J.AHJ.2005.06.014
P407
P577
2006-04-01T00:00:00Z